Education & Training

 

2007 Principles of Gastroenterology for the Nurse Practitioner and Physician Assistant

New Therapies in Liver Disease: HCV, HBV, HE Update CE/CME Post-test

You must complete the evaluation form and each of the tests (or those in which you participated). Once you complete the evaluation form, a certificate with your name and the number of credits you have earned will be created. You will then be able to print your certificate using the print function in your browser.

Select one answer for each question. You may change your answers as many times as you need to until you click the "Submit Post-test " button located at the bottom of the test.

1. Approved therapies for hepatitis C include:

A - Interferon

B - Peg-interferon

C - Ribavirin

D - All of the above

2. The expected sustained viral response to treatment for hepatitis C is:

A - 10%

B - 20%

C - 50%

D - 100%

3. Key issues in achieving successful antiviral therapy include:

A - Patient compliance

B - Patient selection

C - Both A and B

D - None of the above

4. Important question(s) to ask in a non-responder include:

A - Were drug doses modified early in therapy?

B - Was the patient on dialysis?

C - Was the patient compliant?

D - All of the above

5. Viramidine is a new drug in phase 2 trials. It:

A - Has less anemia than ribavirin

B - Has improved efficacy versus ribavirin

C - Has lower efficacy versus ribavirin

D - None of the above

6. VX-950:

A - Is an oral protease inhibitor

B - Has no viral resistance

C - Has more side effects than standard therapy

D - Is FDA approved

7. Tenofovir:

A - Is FDA approved for HIV

B - Is effective in hepatitis B, HIV, co-infected patients

C - May be effective in lamivudine refractory patients

D - All of the above

8. Rifaximin is:

A - An oral, non-absorbed antibiotic

B - Approved for traveler’s diarrhea

C - Used for hepatic encephalopathy

D - All of the above